GlycoEase Sublingual Formula

GlycoEase Sublingual Formula contains the following ingredients:

Serving Size: Approx. 5 Drops (0.19ml)

Servings Per Container: Approx. 160

Amount Per Serving:

• Niacin 1.80 mg
• Gymnema Sylvestre 5.56 mg
• Chromium Polynicotinate 2.4 mcg
• Methylsulfonylmethane (MSM) 0.60 mg
• Vanadyl Sulfate 1.40 mcg
• Boron Chelate 25 mcg

Other Ingredients: Purifed Water, Glycerine, Stevia, Natural Flavors

• Gymnema Sylvestra has the capacity to repair and regenerate pancreas beta cells.
• Vanadyl Sulfate protects pancreatic islets and in so doing, can partially restore insulin production, as well as help maintain healthy glucose levels and glucose tolerance, and healthy levels of fats, creatinine and thyroid hormone, supports correct heart functioning and output of glycerol.
• Chromium Polynicotinate reduces and maintains glucose levels in the blood.
• Niacin (B3) is essential for insulin creation as well as carbohydrate, protein and fat metabolism.

Suggested dosage: 8 drops under the tongue 3-5 times daily. or as directed by your medical provider. Swish in your mouth for approximately 1 minute before swallowing. Best taken 10 minutes or more before meals or an hour or more after a meal.

Consult your doctor before using.

Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus
GS4, an extract of Gymnema leaves, was administered at 400 mg/day to patients with insulin dependent diabetes mellitus (IDDM) on insulin therapy. The results of the study were that insulin requirements and levels of fasting blood glucose, glycosylated haemoglobin (HbA1c), glycosylated plasma protein were reduced. GS4 therapy appears to support revitalization of beta cells.
Ref: Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. J Ethnopharmacol 1990 Oct;30(3):281-94.

Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients
This study reviewed the effectiveness of GS4 in controlling hyperglycaemia. Type 2 diabetic patients on conventional oral medication were given 400 mg/day G4 for 18-20 months as a supplement to their medication. The patients demonstrated a marked reduction in blood glucose, glycosylated haemoglobin and glycosylated plasma protein levels permitting conventional medication dosage to be lowered. 1/4 of the diabetic patients were able to maintain their blood glucose balance with GS4 by itself. The results suggest that pancreas beta cells may actually be regenerated or repaired with G4 supplementation.
Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER. J. Ethnopharmacol 1990 Oct;30(3):295-300.

Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans
This study evaluated the likelihood that glucose tolerance failure arises from insufficient levels of dietary nicotinic acid. Healthy senior volunteers were given either 100 mg nicotinic acid, 200 micrograms Cr, or 200 micrograms Cr + 100 mg nicotinic acid for nearly a month. The researchers suggested that the body's inability to respond to supplementation with chromium might result from inadequate levels of dietary nicotinic acid.
Urberg M, Zemel MB. Metabolism 1987 Sep;36(9):896-9.

Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato) oxovanadium (IV) following acute and chronic administration
It has been demonstrated in both in vitro and in vivo in numerous studies the insulin-related properties of vanadium. Chronic oral administration of inorganic and organic compounds of both vanadium (IV) and vanadium (V) lowered levels of plasma glucose and normalized plasma lipid levels. In this animal study, the goal was to investigate the acute effects of both vanadyl sulfate and bis (maltolato) oxovanadium (IV) (BMOV), an organic vanadium compound, on plasma glucose levels by several routes of administration.
Ref: Can J Physiol Pharmacol. 1995 Jan;73(1):55-64.